{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:19:22Z","timestamp":1790900362566,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In 2002, Zambia withdrew chloroquine as first-line treatment for\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria due to increased treatment failure and worldwide spread of chloroquine resistance. The artemisinin combination regimen, artemether\u2013lumefantrine, replaced chloroquine (CQ) as first choice malaria treatment. The present study determined the prevalence of CQ resistance molecular markers in the\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      and\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      genes in Eastern Zambia at 9 and 13\u00a0years after the removal of drug pressure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Samples collected from Katete District during the drug therapeutic efficacy assessments conducted in 2012 and 2016 were assayed by polymerase chain reaction (PCR) and restriction fragment length polymorphisms (RFLP) to determine the prevalence of genetic mutations, K76T on the\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      gene and N86Y on the\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      gene. A total of 204\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      -positive DBS samples collected at these two time points were further analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the samples analysed for\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      K76T and\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      N86Y in the present study, 112 (82.4%)\n                      <jats:italic>P. falciparum-<\/jats:italic>\n                      infected samples collected in 2012 were successfully amplified for\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      and 94 (69.1%) for\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      , while 69 (65.7%) and 72 (68.6%) samples from 2016 were successfully amplified for\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      and\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      , respectively. In 2012, the prevalence of\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      76K (sensitive) was 97.3%, 76T (resistant) was 1.8%, and 0.8% had both 76K and 76T codons (mixed). Similarly in 2012, the prevalence of\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      86N (sensitive) was 97.9% and 86Y (resistant) was 2.1%. In the 2016 samples, the prevalence of the respective samples was 100%\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      76K and\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      86N.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study shows that there was a complete recovery of chloroquine-sensitive parasites by 2016 in Katete District, Eastern Zambia, 13\u00a0years following the withdrawal of CQ in the country. These findings add to the body of evidence for a fitness cost in CQ-resistant\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      in Zambia and elsewhere. Further studies are recommended to monitor resistance countrywide and explore the feasibility of integration of the former best anti-malarial in combination therapy in the future.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-03859-z","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T04:03:06Z","timestamp":1627444986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9962-7027","authenticated-orcid":false,"given":"Mwenda C.","family":"Mulenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lungowe","family":"Sitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca I.","family":"Ciubotariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonga B.","family":"Hawela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busiku","family":"Hamainza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chipeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungano","family":"Mharakurwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"3859_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/1475-2875-12-437","volume":"12","author":"M Kamuliwo","year":"2013","unstructured":"Kamuliwo M, Chanda E, Haque U, Mwanza-Ingwe M, Sikaala C, Katebe-Sakala C, et al. The changing burden of malaria and association with vector control interventions in Zambia using district-level surveillance data, 2006\u20132011. Malar J. 2013;12:437.","journal-title":"Malar J"},{"key":"3859_CR2","first-page":"11","volume":"1","author":"AB Inambao","year":"2017","unstructured":"Inambao AB, Kumar R, Hamainza B, Makasa M, Nielsen CF. Malaria incidence in Zambia, 2013 to 2015: observations from the health management information system. Health Press Zambia Bull. 2017;1:11\u201321.","journal-title":"Health Press Zambia Bull"},{"key":"3859_CR3","unstructured":"Ministry of Health. National Malaria Control Programme Strategic Plan For FY 2011\u20132015. Lusaka: National Malaria Elimination Centre; 2011. [https:\/\/extranet.who.int\/countryplanningcycles\/sites\/default\/files\/planning_cycle_repository\/zambia\/zambia_malaria_nsp_2011-2015_.pdf]"},{"key":"3859_CR4","unstructured":"Ministry of Health. National Malaria Elimination Strategic Plan 2017\u20132021. Lusaka: National Malaria Elimination Centre; 2017. [https:\/\/static1.squarespace.com\/static\/58d002f017bffcf99fe21889\/t\/5b28d7f1575d1ff0942dbce1\/1529403401067\/National+Malaria+Elimination+Strategic+Plan+2017-Final_PRINT.pdf]"},{"key":"3859_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S2221-1691(13)60030-1","volume":"3","author":"F Masaninga","year":"2013","unstructured":"Masaninga F, Chanda E, Chanda-Kapata P, Hamainza B, Masendu HT, Kamuliwo M, et al. Review of the malaria epidemiology and trends in Zambia. Asian Pac J Trop Biomed. 2013;3:89\u201394.","journal-title":"Asian Pac J Trop Biomed"},{"key":"3859_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1475-2875-7-25","volume":"7","author":"N Sipilanyambe","year":"2008","unstructured":"Sipilanyambe N, Simon JL, Chanda P, Olumese P, Snow RW, Hamer DH. From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia. Malar J. 2008;7:25.","journal-title":"Malar J"},{"key":"3859_CR7","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015."},{"key":"3859_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","volume":"344","author":"A Djimd\u00e9","year":"2001","unstructured":"Djimd\u00e9 A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourt\u00e9 Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257\u201363.","journal-title":"N Engl J Med"},{"key":"3859_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/35002615","volume":"403","author":"MB Reed","year":"2000","unstructured":"Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000;403:906\u20139.","journal-title":"Nature"},{"key":"3859_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.4269\/ajtmh.2011.11-0108","volume":"85","author":"C Setthaudom","year":"2011","unstructured":"Setthaudom C, Tan-ariya P, Sitthichot N, Khositnithikul R, Suwandittakul N, Leelayoova S, et al. Role of Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes on in vitro chloroquine resistance in isolates of Plasmodium falciparum from Thailand. Am J Trop Med Hyg. 2011;85:606\u201311.","journal-title":"Am J Trop Med Hyg"},{"key":"3859_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4269\/ajtmh.2008.78.633","volume":"78","author":"S Zakeri","year":"2008","unstructured":"Zakeri S, Afsharpad M, Kazemzadeh T, Mehdizadeh K, Shabani A, Djadid ND. Association of pfcrt but not pfmdr1 alleles with chloroquine resistance in Iranian isolates of Plasmodium falciparum. Am J Trop Med Hyg. 2008;78:633\u201340.","journal-title":"Am J Trop Med Hyg"},{"key":"3859_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0006-2952(97)00510-8","volume":"55","author":"A Dorn","year":"1998","unstructured":"Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998;55:727\u201336.","journal-title":"Biochem Pharmacol"},{"key":"3859_CR13","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJMoa062032","volume":"355","author":"MK Laufer","year":"2006","unstructured":"Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959\u201366.","journal-title":"N Engl J Med"},{"key":"3859_CR14","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1086\/375419","volume":"187","author":"JG Kublin","year":"2003","unstructured":"Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870\u20135.","journal-title":"J Infect Dis"},{"key":"3859_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12936-015-0850-9","volume":"14","author":"WC Kiarie","year":"2015","unstructured":"Kiarie WC, Wangai L, Agola E, Kimani FT, Hungu C. Chloroquine sensitivity: diminished prevalence of chloroquine-resistant gene marker pfcrt-76 13 years after cessation of chloroquine use in Msambweni. Kenya Malar J. 2015;14:328.","journal-title":"Kenya Malar J"},{"key":"3859_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/1475-2875-13-244","volume":"13","author":"SK Mekonnen","year":"2014","unstructured":"Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clouse RM, Gebru T, et al. Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J. 2014;13:244.","journal-title":"Malar J"},{"key":"3859_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4269\/ajtmh.2006.74.953","volume":"74","author":"H Bogreau","year":"2006","unstructured":"Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, et al. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am J Trop Med Hyg. 2006;74:953\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3859_CR18","doi-asserted-by":"crossref","unstructured":"Mwanza S, Joshi S, Nambozi M, Chileshe J, Malunga P, Kabuya J-BB, et al. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malar J. 2016;15:584.","DOI":"10.1186\/s12936-016-1637-3"},{"key":"3859_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/1475-2875-13-430","volume":"13","author":"B Hamainza","year":"2014","unstructured":"Hamainza B, Masaninga F, Moonga H, Mwenda M, Chanda-Kapata P, Chalwe V, et al. Therapeutic efficacy of artemether-lumefantrine on treatment of uncomplicated Plasmodium falciparum mono-infection in an area of high malaria transmission in Zambia. Malar J. 2014;13:430.","journal-title":"Malar J"},{"key":"3859_CR20","doi-asserted-by":"crossref","unstructured":"Wang X, Mu J, Li G, Chen P, Guo X, Fu L, et al. Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am J Trop Med Hyg. 2005;72:410\u20134.","DOI":"10.4269\/ajtmh.2005.72.410"},{"key":"3859_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.gdata.2016.04.010","volume":"8","author":"HA Antony","year":"2016","unstructured":"Antony HA, Das S, Parija SC, Padhi S. Sequence analysis of pfcrt and pfmdr1 genes and its association with chloroquine resistance in Southeast Indian Plasmodium falciparum isolates. Genom Data. 2016;8:85\u201390.","journal-title":"Genom Data"},{"key":"3859_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12936-019-3031-4","volume":"18","author":"L Sitali","year":"2019","unstructured":"Sitali L, Mwenda MC, Miller JM, Bridges DJ, Hawela MB, Chizema-Kawesha E, et al. En-route to the \u2018elimination\u2019 of genotypic chloroquine resistance in Western and Southern Zambia, 14 years after chloroquine withdrawal. Malar J. 2019;18:391.","journal-title":"Malar J"},{"key":"3859_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/1475-2875-13-458","volume":"13","author":"I Sagara","year":"2014","unstructured":"Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, et al. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. Malar J. 2014;13:458.","journal-title":"Malar J"},{"key":"3859_CR24","unstructured":"Kasonde-Chanshika B, Shimaponda-Mataa NM. Profiling chloroquine resistance-associated Pfcrt-76T and Pfmdr1\u201386Y mutations in Plasmodium falciparum isolates of Ndola, Zambia. Zambia National Health Conference. Lusaka: NHRA. 2018; 204."},{"key":"3859_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1086\/655659","volume":"202","author":"MK Laufer","year":"2010","unstructured":"Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe CV. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis. 2010;202:801\u20138.","journal-title":"J Infect Dis"},{"key":"3859_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12936-019-2716-z","volume":"18","author":"M Ocan","year":"2019","unstructured":"Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, Obuku EA. Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malar J. 2019;18:76.","journal-title":"Malar J"},{"key":"3859_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13071-017-2298-y","volume":"10","author":"F Lu","year":"2017","unstructured":"Lu F, Zhang M, Culleton RL, Xu S, Tang J, Zhou H, et al. Return of chloroquine sensitivity to Africa? Surveillance of African Plasmodium falciparum chloroquine resistance through malaria imported to China. Parasit Vectors. 2017;10:355.","journal-title":"Parasit Vectors"},{"key":"3859_CR28","first-page":"331","volume":"8","author":"G Kishoyian","year":"2018","unstructured":"Kishoyian G, Njagi ENM, Orinda G, Kimani F. Chloroquine sensitivity and prevalence of chloroquine-resistant genes pfcrt and pfmdr-1 in Western Kenya after two decades of chloroquine withdrawal. Ann Med Health Sci Res. 2018;8:331\u20135.","journal-title":"Ann Med Health Sci Res"},{"key":"3859_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/1475-2875-12-415","volume":"12","author":"A Mohammed","year":"2013","unstructured":"Mohammed A, Ndaro A, Kalinga A, Manjurano A, Mosha JF, Mosha DF, et al. Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Malar J. 2013;12:415.","journal-title":"Malar J"},{"key":"3859_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.actatropica.2016.09.008","volume":"164","author":"F Kateera","year":"2016","unstructured":"Kateera F, Nsobya SL, Tukwasibwe S, Hakizimana E, Mutesa L, Mens PF, et al. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Acta Trop. 2016;164:329\u201336.","journal-title":"Acta Trop"},{"key":"3859_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.03647-14","volume":"59","author":"V Baraka","year":"2015","unstructured":"Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, et al. In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2015;59:734\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"3859_CR32","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1086\/596738","volume":"199","author":"C Sisowath","year":"2009","unstructured":"Sisowath C, Petersen I, Veiga MI, M\u00e5rtensson A, Premji Z, Bj\u00f6rkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750\u20137.","journal-title":"J Infect Dis"},{"key":"3859_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12936-017-1995-5","volume":"16","author":"MS Alam","year":"2017","unstructured":"Alam MS, Ley B, Nima MK, Johora FT, Hossain ME, Thriemer K, et al. Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh. Malar J. 2017;16:335.","journal-title":"Malar J"},{"key":"3859_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nyas.12766","volume":"1342","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. 2015;1342:62\u20137.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03859-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03859-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03859-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T04:05:54Z","timestamp":1627445154000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03859-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3859"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03859-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-388401\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the University of Zambia Biomedical Research Ethics Committee (UNZABREC and ERES Converge IRB for TES 2012 and 2016, respectively). Informed consent was obtained from the participants after informing them that blood samples would be used to study malaria after the TES. As this was part of the larger study, permission to utilise the samples was obtained from National Malaria Elimination Centre, ministry of health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}